NEW YORK (
CHANGE IN RATINGS
(BRCM - Get Report) was added to the Conviction Buy List at Nomura. Valuation is attractive at 13 times CY13E EPS.
(BTU - Get Report) was upgraded at Goldman Sachs from Neutral to Buy. $37 price target. Macro data is improving in China, and the company is leveraged to higher PRB prices, Goldman said.
(COP - Get Report) was upgraded at Citigroup to Buy from Neutral. $67 price target. Opportunistic entry point from split-up, Citigroup said.
(EVER - Get Report)
was initiated with a Neutral rating at Goldman Sachs. $13 price target. Margins will be pressured by lower interest rates, Goldmans said.
Everbank Financial was initiated with an Outperform rating at Keefe, Bruyette & Woods. $14 price target. Company is a well-managed, fast-growing bank, KBW said.
(FL - Get Report)
was upgraded at Deutsche Bank from Hold to Buy. $38 price target. Higher sales are driving wider margins, Deutsche said.
was upgraded at Needham from Hold to Buy. $13 price target. Cost improvements should attract value investors, Needham said.
Jack in the Box
was upgraded at Wedbush Securities from Underperform to Neutral. $25 price target. Industry pricing and commodity costs are improving, Wedbush said.
was upgraded at Oppenheimer to Neutral from Underperform. Valuation now reflects headwinds, Oppenheimer said.
was upgraded at Stifel Nicolaus from Hold to Buy. $53 price target. Stock is attractive, following a 12% pullback, Stifel Nicolaus said.
was upgraded at BMO Capital Markets to Outperform from Market Perform. $30 price target. Decline in share price represents buying opportunity, BMO said.
STOCK COMMENTS / EPS CHANGES
estimates were boosted through 2013 at Sterne Agee. Company boosted its guidance, Sterne Agee said. Buy rating and $30 price target.
price target was raised at Morgan Stanley. Shares are now seen reaching $51. Company is realizing higher margins at ABC, and the
movie has performed well, Morgan Stanley said. Overweight rating.
was added to the Conviction Buy List at Goldman Sachs. Selloff in energy names appears overdone, Goldman said. $149 price target.
estimates, price target were raised at Bank of America/Merrill Lynch. Shares are now seen reaching $41. Estimates were also increased, given higher Medicare RACs, BofA/Merrill said. Buy rating.